Country: Slovakia

Currently showing 20 clinical trials. Use pagination links to see more trials.

  • CT-EU-00117573

    Study of Combination Therapy for Melanoma After Anti-PD-1 Treatment

    This clinical trial is comparing two different treatment approaches for advanced melanoma, which is a type of skin cancer that has spread to other parts of the body. If you have a specific gene mutation called BRAF and have previously received treatment with certain immunotherapy drugs like nivolumab or pembrolizumab, you may be eligible for this study.

    One treatment approach involves receiving three study medicines: pembrolizumab given through an IV every 3 weeks, along with encorafenib and binimetinib taken by mouth daily at home. The other approach involves receiving two study medicines: ipilimumab and nivolumab given through an IV every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatment approaches will be given for around 2 years, but there is no time limit for the encorafenib and binimetinib treatment.

    The study team will closely monitor your condition during regular visits to the clinic to see how you are responding to the treatment. The main goal is to determine which treatment approach is more effective in shrinking or eliminating the melanoma tumors. Around 150 participants will be enrolled in this study and randomly assigned to one of the two treatment groups.

    CzechiaGermanyItalyPolandSlovakiaSpainUnited Kingdom
  • Study of a New Drug for Moderate to Severe Rotator Cuff Tendinopathy

    This here clinical trial is aimin’ to see if a new medicine called secukinumab can help folks with moderate to severe rotator cuff tendinopathy, which is a painful condition affectin’ the shoulder. The study will compare secukinumab to a placebo, which is like a fake medicine with no real effects.

    Now, if you join this trial, you’ll be given either secukinumab or the placebo by injection under the skin every week or so for the first few months. The doctors won’t know which one you’re gettin’ until later. You’ll also need to keep takin’ any anti-inflammatory medicines and doin’ physical therapy exercises as you normally would.

    The main thing the researchers are lookin’ at is whether secukinumab can better improve your physical shoulder symptoms like pain, weakness, stiffness, and such compared to the placebo. They’ll be askin’ you to rate your symptoms at different points durin’ the 24-week study.

    It’s important to know that you can’t increase your anti-inflammatory medicine doses or get steroid injections durin’ the study, but you can take other pain meds like acetaminophen if needed. The study involves some medical tests too, like MRI scans and X-rays of your shoulder.

    So in a nutshell, this trial aims to find out if secukinumab works better than a placebo at relievin’ the symptoms of rotator cuff tendinopathy when combined with standard treatments like physical therapy and anti-inflammatory drugs. If you’re interested, you’d be closely monitored and get either the new medicine or a placebo for free as part of the study.

    BulgariaCzechiaDenmarkFrancePortugalSlovakiaUnited Kingdom
  • Study Comparing Asciminib and Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia

    This study examines the effects and tolerance of two drugs, asciminib and nilotinib, for treating a specific type of leukemia called Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in its chronic phase. The participants are adults who have been newly diagnosed and have not received previous treatment for this condition. They will be randomly assigned to receive either asciminib or nilotinib. The study aims to see which drug is better tolerated and how effective they are. Throughout the study, participants will be monitored for any side effects and the progress of their treatment until they either experience significant side effects, the disease progresses, or they decide to stop the treatment. Follow-up checks will also be conducted after the treatment ends.

    BulgariaCzechiaFranceGermanyGreeceHungaryItalyNetherlandsRomaniaSlovakiaUnited Kingdom
  • Study of the new oral drug LY3871801 for rheumatoid arthritis

    The aim of this study is to test a new drug called LY3871801 for people suffering from moderate to severe rheumatoid arthritis. The main goal is to see if this new drug can help reduce disease activity and improve symptoms better than a placebo. In the first part of the study, doctors will check how much the Disease Activity Score changes after 12 weeks of taking LY3871801 or a placebo. Then, in the second part, they will look at what percentage of patients experience significant improvement, defined as achieving an ACR50 response, which means reducing symptoms of rheumatoid arthritis by 50% or more. Both the real drug and the placebo will be taken by mouth.

    CzechiaFranceGermanySlovakiaUnited Kingdom
  • Efficacy and safety study of rosnilimab in moderate to severe rheumatoid arthritis

    This study will evaluate the effectiveness and safety of Rosnilimab in patients with moderate to severe rheumatoid arthritis. Rosnilimab is an antibody that activates the PD-1 receptor, also known as ANB030. Patients will be randomly assigned to receive Rosnilimab or placebo.

    The main aim of the study is to assess changes in the 28-Joint Disease Activity Index based on the concentration of C-reactive protein (DAS28-CRP) after 12 weeks of treatment. DAS28-CRP is a validated tool that assesses disease activity based on the number of painful and swollen joints and the concentration of C-reactive protein in the blood. A reduction in DAS28-CRP indicates an improvement in the patient’s condition.

    This study aims to test whether Rosnilimab is effective and safe in the treatment of rheumatoid arthritis. If the results are promising, this drug could become a new treatment option for patients suffering from this disease.

    BelgiumGermanyHungaryItalyPolandSlovakiaSpain
  • Comparison of zibotentan/dapagliflozin with dapagliflozin alone in the treatment of chronic kidney disease with high proteinuria

    The study aims to understand how to better treat people with chronic kidney disease (CKD) and high proteinuria. This study is in its third phase and involves multiple centers where participants will be closely monitored. The main goal is to compare the effectiveness, safety, and how well participants tolerate a combination treatment of zibotentan/dapagliflozin versus dapagliflozin alone.

    During this study, participants will be randomly assigned to one of two groups. One group will receive the combination of zibotentan and dapagliflozin, while the other group will receive only dapagliflozin. Both treatments aim to slow down the decline in kidney function, which is a major concern for people with CKD and high proteinuria. The key measure of success for this study is the change in eGFR from baseline, which is a test used to check how well the kidneys are working, specifically by measuring the estimated glomerular filtration rate (eGFR). This will be assessed at the 24-month mark of the study.

    This research is crucial because it could lead to better treatment options for those suffering from CKD and high proteinuria, potentially improving their quality of life and health outcomes.

    AustriaBulgariaDenmarkFranceGermanyItalyNetherlandsNorwayPolandSlovakiaSpainSwedenUnited Kingdom
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    AustriaBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Studying efficacy of volrustomig for metastatic lung cancer

    The study compared two treatments for metastatic non-small cell lung cancer: volrustomig with chemotherapy and pembrolizumab with chemotherapy. Its purpose is to determine which combination is more effective and safer. Patients will be divided into two groups. One group will receive volrustomig and chemotherapy, and the other group will receive pembrolizumab and chemotherapy. The effectiveness of treatment in each group will then be tracked using imaging tests. In addition, a group of researchers will follow each participant until the end of the study to make sure the treatment is safe and tolerable.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    AustriaBelgiumFranceGermanyItalyNetherlandsNorwayPolandPortugalSlovakiaSpainUnited Kingdom
  • Exploring the effects and safety of new therapy for Symptomatic Knee Osteoarthritis

    This study is a test of a medication called DFV890, focusing on its effectiveness, safety, and tolerance among individuals with arthritis in their knee, which causes significant pain. Some participants receive the actual medication, while others receive a ‘placebo’ with no active substance. Importantly, neither the participants nor their doctors are aware of which treatment they are receiving. The study duration is slightly over 5 months, and the primary objective is to assess whether DFV890 can help reduce knee pain.

    CzechiaGermanyHungaryRomaniaSlovakiaSpain
  • Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    AustriaBulgariaCzechiaGermanyGreeceHungaryNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    AustriaBulgariaCzechiaFranceGermanyItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Iptacopan’s effect on adult patients with atypical hemolytic uremic syndrome

    This study is conducted to understand if a medicine called iptacopan (also known as LNP023) is safe and effective in treating a disease called Atypical Hemolytic Uremic Syndrome (aHUS) in adults who have never received a type of medication known as a complement inhibitor. Around 50 adults will be given 200 mg of this iptacopan pill twice a day. The doctors will measure how their illness responds by looking at blood tests, kidney health, how often they need to have their blood cleansed by a machine (dialysis), the progression of their kidney illness, and how they feel energetically and about their quality of life. Side effects of taking iptacopan will be recorded for a year.

    AustriaCzechiaGreeceSlovakiaSloveniaUnited Kingdom
  • Study investigating new medicine for advanced metastatic breast cancer

    A clinical study is investigating the impact and safety of a new medicine named ARV-471 (Vepdegrestrant), contrasting its effects with an already-used drug called fulvestrant (FUL). This research targets individuals suffering from advanced metastatic breast cancer, a disease that often spreads to various parts of the body and is challenging to control. ARV-471 will be given to half of the participants, with the other half receiving fulvestrant. The effects of both will be monitored over time. ARV-471 is consumed by mouth, while FUL is administered through injections.

    BelgiumBulgariaCzechiaFinlandFranceGermanyGreeceHungaryItalyNorwayPolandSlovakiaSpainSwedenUnited Kingdom
  • Testing safety and effects of telisotuzumab and docetaxel in Lung Cancer patients

    This study is for adults who have been treated before for a type of lung cancer called non-small cell lung cancer (NSCLC). The aim is to see if a new drug, called telisotuzumab vedotin, works better and is as safe as a common drug called docetaxel. In this study, cancer activity and any side-effects will be observed closely. The treatment will be given by a drip into a vein.The researchers will randomly decide whether each participant will get telisotuzumab vedotin or docetaxel, with an equal chance of getting either drug. While in the study, each person will have regular hospital or clinic visits to check how they are doing with tests and questionnaires.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Evaluating the efficacy of macitentan in the treatment of high pulmonary artery blood pressure

    This study is checking if a 75 mg dose of a medicine called Macitentan can do a better job for patients with a lung condition called Pulmonary Arterial Hypertension (PAH) compared to a 10 mg dose. The main goal is to see if the 75 mg dose can better delay the patient’s first major health event related to PAH. Major events include things like unplanned hospital stays related to PAH, or their PAH getting worse. The researchers will check if patients’ PAH gets worse by looking at things like their physical exercise ability and signs of heart failure. The study also looks at how patients’ symptoms change from day to day.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalSlovakiaSpainSwedenUnited Kingdom
  • Study on Aticaprant’s safety and effects as an adjunctive therapy for major depressive disorder

    This trial is for adults and elders who are struggling with major depressive disorder (MDD). The trial involves a medicine called aticaprant, and this is supposed to be taken alongside what they are already using to handle their depression (SSRI or SNRI drugs). The study aims to determine the long-term safety and efficacy of aticaprant. To achieve this, close monitoring of adverse events, which includes negative reactions or changes in patients’ health, is crucial. Physical health indicators, such as weight, core body temperature, heart rate, and blood pressure, will be assessed to understand the potential impact of aticaprant. Additionally, the study will evaluate patients’ thoughts on suicide, any discernible changes in their sexual health, and their overall mood.

    BelgiumBulgariaCzechiaFranceHungaryItalyPolandSlovakiaSpainSweden
  • Study of alpelisib and fulvestrant for advanced breast cancer treatment

    This trial is looking at the effects of the combined use of two drugs, alpelisib and fulvestrant, in treating patients who have advanced breast cancer. The cancer should be HR-positive and HER2-negative, and have a specific mutation (PIK3CA). If the patients already underwent certain other treatments like CDK4/6 Inhibitors and aromatase Inhibitors, but the cancer has progressed, they could join this trial. Doctors will be able to compare the results of patients taking alpelisib and fulvestrant together, with those taking fulvestrant with a placebo, They aim to check which combination works better in delaying the advance of cancer or in improving a patient’s life duration.

    BelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyPolandPortugalRomaniaSlovakiaSpain
  • Comparing remibrutinib and teriflunomide for Multiple Sclerosis

    This study is all about comparing two treatments for relapsing multiple sclerosis (RMS)—a medicine called remibrutinib and another one called teriflunomide. Initially, researchers will do what’s known as a ‘double-blind, which means neither the participants nor the researchers know which treatment the participant takes. This part of the study will involve about 800 people and will go for up to 30 months. After this, the participants can continue the study openly taking remibrutinib for up to 5 years. The study will measure things like how often the MS relapses, changes in disability scale, amount of new lesions, changes in blood markers, walking and arm function, mood, pain, and deviations in various health parameters. There will be a lesser version trial simultaneously, with results from both pooled for analysis.

    BelgiumBulgariaDenmarkItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Evaluating epilepsy treatment with brivaracetam

    This study aims to see how effective and safe a drug called Brivaracetam is for children and young adults aged between 2 and 25 who have a type of epilepsy known as Absence Epilepsy. Brain activity will be recorded for 24 hours using a device on day 14. If the patient has not had an episode of epilepsy in the 4 days before the recording or during it, they are considered ‘free’ of seizures. If the patients experience a seizure, it will be recorded on the machine and these patients have to leave the study. These patients also should not be taking a type of drug known as benzodiazepine during the study. All people taking part will have to keep a diary of their seizures from the start of the study until the end.

    BelgiumItalyRomaniaSlovakiaSpain